Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Keep learning. Excel in your career. Choose from more than 200 courses in seven different categories, taught by experts in the chemistry community, online and in person.
LONDON – Swiss startup T3 Pharma AG has raised CHF25 million (US$26.7 million) in a series C round, to fund a 100-patient phase I/II study of its live bacteria cancer immunotherapy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results